Xiaoyan Liu, Weidi Xiao, Yanan Zhang, Sandra E. Wiley, Tao Zuo, Yingying Zheng, Natalie Chen, Lu Chen, Xiaorong Wang, Yawen Zheng, Lan Huang, Shixian Lin, Anne N ...

Researchers from IOCB Prague are furthering the understanding of how medicines work and what it takes to develop their most effective variants. In one current study, they have focused on the disease ...

At the recent Celebration of Native Mass Spectrometry in Oxford, we caught up with Michal Sharon to talk about her research and the fascinating evolutionary history of the 20S proteasome. Would you ...

About 40 percent of people over age 65 suffer some form of age-related memory loss, which puts them at higher risk for developing dementia and Alzheimer's disease. However, there are currently no ...

Many therapeutic targets escape druggability by mysterious molecular motions that cannot be precisely visualized. This ‘dark-world’ reality is particularly augmented in the ubiquitin-proteasome system ...

Booster Therapeutics has announced its inception, backed by a $15m investment, to develop a new class of proteasome activator medicines aimed at treating neurodegenerative diseases and other complex ...

Alzheimer's disease is the most well-known neurodegenerative disorder where tau dysfunction plays a role. But there are easily a half-dozen tauopathies that vary in some aspects, but share the ...

Booster Therapeutics is developing a novel therapeutic approach that aims to combat the accumulation of deviant proteins in cells, which are a major driver of Parkinson's and other complex diseases ...

Success as An Anti-Cancer Agent Has Fueled Efforts to Discover Proteasome Inhibitors That Raise Proteins Levels with Beneficial Effects The ubiquitin proteasome system (UPS) provides a mechanism for ...